These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32356125)

  • 21. Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure.
    Lowe RH; Abraham TT; Darwin WD; Herning R; Cadet JL; Huestis MA
    Drug Alcohol Depend; 2009 Nov; 105(1-2):24-32. PubMed ID: 19631478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of forensic specimens for cannabinoids. II. Relationship between blood delta 9-tetrahydrocannabinol and blood and urine 11-nor-delta 9-tetrahydrocannabinol-9-carboxylic acid concentrations.
    Moody DE; Monti KM; Crouch DJ
    J Anal Toxicol; 1992; 16(5):302-6. PubMed ID: 1338218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Residual cannabis levels in blood, urine and oral fluid following heavy cannabis use.
    Odell MS; Frei MY; Gerostamoulos D; Chu M; Lubman DI
    Forensic Sci Int; 2015 Apr; 249():173-80. PubMed ID: 25698515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and Verification of a Linked
    Patilea-Vrana GI; Unadkat JD
    Drug Metab Dispos; 2021 Jul; 49(7):509-520. PubMed ID: 33952608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extended plasma cannabinoid excretion in chronic frequent cannabis smokers during sustained abstinence and correlation with psychomotor performance.
    Karschner EL; Swortwood MJ; Hirvonen J; Goodwin RS; Bosker WM; Ramaekers JG; Huestis MA
    Drug Test Anal; 2016 Jul; 8(7):682-9. PubMed ID: 26097154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An Approach to Biomarker Discovery of Cannabis Use Utilizing Proteomic, Metabolomic, and Lipidomic Analyses.
    Hinckley JD; Saba L; Raymond K; Bartels K; Klawitter J; Christians U; Hopfer C
    Cannabis Cannabinoid Res; 2022 Feb; 7(1):65-77. PubMed ID: 33998853
    [No Abstract]   [Full Text] [Related]  

  • 27. Assessment of driving capability through the use of clinical and psychomotor tests in relation to blood cannabinoids levels following oral administration of 20 mg dronabinol or of a cannabis decoction made with 20 or 60 mg Delta9-THC.
    Ménétrey A; Augsburger M; Favrat B; Pin MA; Rothuizen LE; Appenzeller M; Buclin T; Mangin P; Giroud C
    J Anal Toxicol; 2005; 29(5):327-38. PubMed ID: 16105257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Driving Under the Influence of Marijuana Versus Driving and Dying Under the Influence of Marijuana: A Comparison of Blood Concentrations of Δ9-Tetrahydrocannabinol, 11-Hydroxy-Δ9-Tetrahydrocannabinol, 11-Nor-9-Carboxy-Δ9-Tetrahydrocannabinol and Other Cannabinoids in Arrested Drivers Versus Deceased Drivers.
    Lemos NP; San Nicolas AC; Volk JA; Ingle EA; Williams CM
    J Anal Toxicol; 2015 Oct; 39(8):588-601. PubMed ID: 26378132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and validation of an automated liquid-liquid extraction GC/MS method for the determination of THC, 11-OH-THC, and free THC-carboxylic acid (THC-COOH) from blood serum.
    Purschke K; Heinl S; Lerch O; Erdmann F; Veit F
    Anal Bioanal Chem; 2016 Jun; 408(16):4379-88. PubMed ID: 27116418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol.
    Hartman RL; Brown TL; Milavetz G; Spurgin A; Gorelick DA; Gaffney G; Huestis MA
    Clin Chem; 2015 Jun; 61(6):850-69. PubMed ID: 26019183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cannabinoid-deficient Benin republic hemp (Cannabis sativa L.) improves semen parameters by reducing prolactin and enhancing anti-oxidant status.
    Alagbonsi AI; Olayaki LA; Abdulrahim HA; Adetona TS; Akinyemi GT
    BMC Complement Altern Med; 2019 Jun; 19(1):132. PubMed ID: 31208410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psychomotor performance in relation to acute oral administration of Delta9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects.
    Roser P; Gallinat J; Weinberg G; Juckel G; Gorynia I; Stadelmann AM
    Eur Arch Psychiatry Clin Neurosci; 2009 Aug; 259(5):284-92. PubMed ID: 19224107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Serum cannabinoid levels 24 to 48 hours after cannabis smoking].
    Skopp G; Richter B; Pötsch L
    Arch Kriminol; 2003; 212(3-4):83-95. PubMed ID: 14639811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids.
    Goodwin RS; Gustafson RA; Barnes A; Nebro W; Moolchan ET; Huestis MA
    Ther Drug Monit; 2006 Aug; 28(4):545-51. PubMed ID: 16885723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urinary concentrations of benzophenone-type ultra violet light filters and reproductive parameters in young men.
    Adoamnei E; Mendiola J; Moñino-García M; Vela-Soria F; Iribarne-Durán LM; Fernández MF; Olea N; Jørgensen N; Swan SH; Torres-Cantero AM
    Int J Hyg Environ Health; 2018 Apr; 221(3):531-540. PubMed ID: 29449081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cannabis Edibles: Blood and Oral Fluid Cannabinoid Pharmacokinetics and Evaluation of Oral Fluid Screening Devices for Predicting Δ
    Newmeyer MN; Swortwood MJ; Andersson M; Abulseoud OA; Scheidweiler KB; Huestis MA
    Clin Chem; 2017 Mar; 63(3):647-662. PubMed ID: 28188235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral fluid cannabinoids in chronic, daily Cannabis smokers during sustained, monitored abstinence.
    Lee D; Milman G; Barnes AJ; Goodwin RS; Hirvonen J; Huestis MA
    Clin Chem; 2011 Aug; 57(8):1127-36. PubMed ID: 21677094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ABCB1 C3435T polymorphism is associated with tetrahydrocannabinol blood levels in heavy cannabis users.
    Kebir O; Lafaye G; Blecha L; Chaumette B; Mouaffak F; Laqueille X; Benyamina A
    Psychiatry Res; 2018 Apr; 262():357-358. PubMed ID: 28917442
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can a threshold for 11-nor-9-carboxy-Δ
    Zinka B; Epple S; Schick S; Skopp G; Graw M; Musshoff F
    Drug Test Anal; 2019 Feb; 11(2):325-330. PubMed ID: 30193411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Tetrahydrocannabinol pharmacokinetics; new synthetic cannabinoids; road safety and cannabis].
    Goullé JP; Guerbet M
    Bull Acad Natl Med; 2014 Mar; 198(3):541-56; discussion 556-7. PubMed ID: 26427296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.